home / stock / kaltf / kaltf news

KALTF News and Press, Kalytera Therapeutics From 07/26/21

Stock Information
Company Name: Kalytera Therapeutics
Stock Symbol: KALTF
Market: OTC
Website: kalytera.co
Menu
KALTF KALTF Quote KALTF Short KALTF News KALTF Articles KALTF Message Board
Get KALTF Alerts

News, Short Squeeze, Breakout and More Instantly...
KALTF - Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company's Nitric Oxide-Releasing Compound, R-107

SAN FRANCISCO and TORONTO, July 26, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that a recently published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust ...
KALTF - Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease

SAN FRANCISCO and TORONTO, July 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") is pleased to provide additional detail regarding exceptionally positive data with R-107 in a validated animal model of pu...

KALTF - Claritas Announces Effective Date for Share Consolidation

SAN FRANCISCO, July 20, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") is pleased to announce that the previously disclosed consolidation of its Common Shares (the " Consolidation ") has recei...

KALTF - Claritas Announces Commitments from Company's Largest Shareholders to Vote for Approval of Share Consolidation

SAN FRANCISCO and TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced that it has received commitments from the Company’s two l...
KALTF - Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics

SAN FRANCISCO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has entered into an agreement (the “Debt Forgiveness Agreement” ) with ...

KALTF - Claritas Pharmaceuticals Issues Letter to Shareholders

SAN FRANCISCO and TORONTO, May 11, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE (TSXV): CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today issued the following letter to shareholders from Robert Farrell, the Comp...

KALTF - Claritas inks deal with CMAX Clinical Research for early-stage R-107 study

Claritas Pharmaceuticals ([[KALTF]] +16.1%) has entered into an agreement with CMAX Clinical Research to conduct a randomized, placebo-controlled, single-blind, single ascending dose Phase 1 clinical study to evaluate the pharmacokinetics and safety profile of R-107.The study is expected to b...
KALTF - Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107

SAN FRANCISCO and TORONTO, April 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has entered into an agreement with CMAX Clinical Research Pty Ltd ( “CMAX” ) to...

KALTF - Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH

SAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has entered into a binding Letter of Intent (the “LOI” ) with Salzman Group, In...

KALTF - Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients

SAN FRANCISCO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that, based on significantly positive results in a controlled large animal model of sepsis...
Previous 10 Next 10